Navigation Links
Risk of heart disease begins in teens

New study on individuals with type 1 diabetes reveal that they have more chances of developing heart disease by the time they reach their teens.

The findings were based on study done on a group of adolescents whose age was ranging from 12 to 21 years, without type 1 diabetes. It was found that there was substantial fatty plaque buildup inside the arteries regardless of body weight, family history, smoking and length of time with diabetes. These individuals are particularly susceptible to atherosclerosis. The findings were recently presented at a meeting of the American Dietetics Association (ADA).

Type 1 diabetes is an autoimmune disorder in which the body no longer produces insulin, the hormone that clears the blood of glucose after a meal and deposits it into body cells to use as fuel. Patients must inject insulin several times a day to manage the disease. Complications of diabetes include heart disease, kidney failure, blindness and limb amputation.

According to the ADA, atherosclerosis accounts for roughly 1.5 million heart attacks and 600,000 strokes each year, in the general population.

According to researchers patients with more plaque inside their arteries also had higher levels of blood fats such as LDL ,"bad" cholesterol, and increased blood homocysteine, a substance that is associated with heart disease risk.

Dr. Jody S Krantz, author of the study feels that early intervention is warranted and is mandatory in adolescents and young adults suffering from diabetes and possible association with atheroscerosis.
'"/>




Page: 1

Related medicine news :

1. Starvation in pregnant women can cause heart disease to their children
2. Individuals with sleep related breathing disorders more prone to heart disease
3. And now they say infections can cause heart disease!!!!
4. And now they say infections can cause heart disease!!!!
5. Award for TTK Chitra heart valve prosthesis
6. Eat greens to have a ever green heart
7. Asthma! A new warning for heart disease
8. Protein in urine foresees heart disease
9. One...just one cigarette can spoil the heart function.
10. Beer vitamin protects heart
11. Hostility can hurt your heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Risk heart disease begins teens

(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...nce of Oral and Overall Health, HARRISBURG, Pa., ...ted,Concordia Dental is celebrating National Smile...a and the British Dental Health Foundation to,prom...h. Beginning May 18,this year,s event is launchin...it the largest independent international dental he...
(Date:5/16/2008)...nefit from calcitriol, an oral form , , ...d vitamin D may cut the risk of death for people w...bout one quarter, a new study suggests. , Duri...hose being treated with calcitriol, an oral form o...eath lowered by 26 percent when compared with thos...
(Date:5/16/2008)...niors and People With,Disabilities, OAKLAND, Cali...,homecare workers across the state are outraged by...rs of service, wages and benefits,which would for...d the,people they serve deeper into poverty. They ...nd people with disabilities from Schwarzenegger,s,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
... found a herb used in traditional Indian medicine ...nsulin levels // in a manner similar to prescripti...a herb called salacia oblonga, which is native to ...oblonga binds to intestinal enzymes that break dow...
...reveals that a compound in carrots may reduce the ...ve found // that falcarinol, a natural pesticide f...duces the risk of developing cancer. Falcarinol pr...h as licorice rot, which causes black spots on the...
...y that looked at how in utero exposures affect the... say, larger babies // have a higher risk of devel...ay associations between larger birth weight and in... proposed, but there have been few studies to exam...
...disease are more likely to suffer from atheroscler...d to heart attack // or stroke shows latest resear...ria levels in the mouths of 657 people who had no ...hickness of the subjects' carotid artery, used to ...
Other Medicine News:
(Date:5/16/2008)...l Biomarkers -- for Lung Cancer Diagnosis and, Ide...r of Unknown Primary ...Types With High Sensitivity and, Specificity and...ncer Results of microRNA Signature to Identify Ti...ding 90% and Specificity of 99%, REHOVOT, Israel ...
(Date:5/15/2008)...May 15 /- Eisai Corporation of North,...cal data abstracts about,compounds in the company,...ical oncology research have been accepted for pres...n Society of Clinical Oncology (ASCO),taking plac... variety of abstracts on Eisai marketed products a...
(Date:5/15/2008)...at ASCO Showed Acceptable Tolerability Profile, ...opathy, WOODCLIFF LAKE, N.J., May 15 /PRNewswire/...bulin mesylate (E7389) demonstrated activity in a,...y advanced or metastatic,breast cancer, according ...al. The study also suggests that eribulin mesylate...
(Date:5/15/2008)... 15 /- Sanofi-aventis,(EURO...ings from the,landmark ATHENA study showed Multaq(...tment of patients with atrial fibrillation or atri...ospitalizations or death from any,cause by a stati...he study,primary endpoint. The ATHENA results will...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results 11118 1Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 1Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 2Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 3Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 4Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension 11113 1Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension 11113 2SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 1SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 2SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 3
...orted by the,National Institutes of Healths Nati...and Skin Diseases (NIAMS) shows that the,anticon... certain,types of seizures, can be an effective ...ated with the common, often hard-to-treat,chroni...onsored, randomized, double-blind clinical trial,...
...via COMTEX News,Network) -- Myriad Genetics, Inc. ...ww.myriad.com/">www.myriad.com ),announced today t...taggered Start" and a "Randomized Withdrawal" clin...d Start" clinical trial,design at the Alzheimer,s ..., 2007, in Washington, D.C. The analysis demonstra...
Other Medicine Technology:Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches.
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches.
Medicine Products: